Seres Therapeutics sheds about 160 jobs to focus on commercial C. diff pill
Seres Therapeutics will end most R&D work to focus resources on its commercial product in a move that will result in letting go about 160 workers, or 41% of the staff, the biotech said Thursday morning.
The Boston biotech said it will place priority on its pill Vowst, which secured FDA approval in April for patients recovering from repeating infections of Clostridioides difficile, commonly called C. diff.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.